MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-24-2026
Achieve Life Sciences P/E Ratio 2011-2026 | ACHV
Annual P/E Ratio Achieve Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.31 | -2.34 | -3.03 | -1.14 | -1.91 | -1.5 | -0.277 | -0.404 | -0.72 | -0.803 | -1.03 | -1.39 | -5.04 | -8.52 | -9.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.277 | -9.2 | -2.64 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-66.5 | $ 3.8 | 5.33 % | $ 9.14 B |  Australia |
 |
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-0.583 | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-1.16 | $ 2.63 | -1.22 % | $ 16.5 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | Canada |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
6.11 | $ 88.34 | -3.22 % | $ 27.2 B | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-467 | $ 3.41 | -3.67 % | $ 230 B | Britain |
 |
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-2.17 | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
130 | $ 316.2 | -4.28 % | $ 41.4 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-4.65 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-0.608 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
12.2 | $ 4.44 | -0.67 % | $ 730 M | Britain |
 |
Atreca
BCEL
|
-0.504 | - | -11.76 % | $ 5.79 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-0.077 | - | -11.43 % | $ 502 K | USA |
 |
argenx SE
ARGX
|
-33.7 | $ 743.15 | -0.68 % | $ 25 B |  Niderland |
 |
Завод ДИОД
DIOD
|
17.7 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-3.81 | - | - | - | Russia |
 |
Applied Molecular Transport
AMTI
|
-0.175 | - | - | $ 10.1 M | USA |
 |
Aptorum Group Limited
APM
|
-0.958 | $ 0.89 | - | $ 4.85 M | China |
 |
Applied Therapeutics
APLT
|
-4.52 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | USA |
 |
Teligent, Inc.
TLGT
|
-0.879 | - | -13.85 % | $ 16.1 M | USA |
 |
Cerus Corporation
CERS
|
-31.7 | $ 1.8 | -2.7 % | $ 343 M | USA |
 |
AbbVie
ABBV
|
220 | $ 202.28 | -2.11 % | $ 358 B | USA |
 |
Aquestive Therapeutics
AQST
|
-5.58 | $ 4.04 | -1.28 % | $ 432 M | USA |
 |
Aravive
ARAV
|
-0.791 | - | -13.39 % | $ 1.45 M | USA |
 |
Viela Bio, Inc.
VIE
|
-2.83 | - | - | $ 2.91 B | USA |
 |
Coherus BioSciences
CHRS
|
1.35 | $ 1.63 | -2.69 % | $ 191 M | USA |
 |
AbCellera Biologics
ABCL
|
-6.57 | $ 3.32 | -2.06 % | $ 992 M | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
-3.3 | $ 8.12 | -1.22 % | $ 222 M |  Israel |
 |
Ardelyx
ARDX
|
-26.3 | $ 5.8 | -2.93 % | $ 1.4 B | USA |